A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone

Journal of Hypertension

Volumn 14, Issue 11, 1996, Pages 1325-1330

  Chen, Sufang ^a   Noguchi, Yuichi ^a   Izumida, Taro ^a   Tatebe, Junko ^a   Katayama, Shigehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin II receptor antagonist fructose fed rats; Insulin resistance; Insulin sensitizer

Indexed keywords

ALACEPRIL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FRUCTOSE; GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CELL MEMBRANE; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; IMMUNOBLOTTING; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029968957     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199611000-00011     Document Type: Article

References (37)

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
2. Ferrannini E: Insulin resistance in essential hypertension. N Engl J Med 1987, 317:350-357.
3. Modan M, Halkin H, Almog S, Lusky A, Eskol A, Shefi M, et al.: A link between hypertension, obesity and glucose intolerance. J Clin Invest 1985, 75:809-817.
4. DeFronzo RA, Ferrannini E: Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14: 173-194.
5. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ: The effects of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975, 55:845-855.
6. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L: Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981, 30:219-225.
7. Pfiefle B, Ditschuneit H: Effect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologia 1981, 20:155-158.
8. Moore RD: Effect of insulin upon ion transport. Biochim Biophys Acta 1983, 737:1-49.
9. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992, 15:193-203.
10. Colca JR, Morion DR: Antihyperglycaemic thiazolidinediones: ciglitazone and its analogues. In New Antidiabetic Drug. Edited by Bailey CJ, Flatt PR. London: Smith-Gordon Publishers; 1990:255-262.
11. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, et al.: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 1993, 42:75-80.
12. Lee MK, Miles Philip DG, Khoursheed M, Gao KM, Moossa AR, Olefsky JM: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rats. Diabetes 1994, 43:1435-1439.
13. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD: Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes 1994, 43:204-211.
14. Katayama S, Abe M, Kashiwabara H, Kosegawa I, Ishii J: Evidence against a role of insulin in hypertension in spontaneously hypertensive rats: CS-045 does not lower blood pressure despite improvement of insulin resistance. Hypertension 1994, 23:1071-1074.
15. Rett K, Lotz N, Wicklmayr M, Fink E, Jauch KW, Gunther B, et al.: Verbesserte Insulinwirkung durch ACE-Hemmung beim Type-II-Diabetiker. Deutsch Med Wochenschr 1988, 113:243-249.
16. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868-873.
17. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J: Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care 1990, 13:1109-1111.
18. Santoro D, Natali A, Palombo C, Brandi LS, Piatti M, Ghione S, et al.: Effects of chronic angiotensin converting enzyme inhibitor on glucose tolerance and insulin sensitivity in essential hypertension, Hypertension 1992, 20:181-191.
19. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Kajiwara N: Kinin contributes to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 1994, 23: 450-455.
20. Hartl WH, Jauch KW, Herndon DN, Cohnert TU, Wolfe RR, Schildberg FW: Effect of low-dose bradykinin on glucose metabolism and nitrogen balance in surgical patients. Lancet 1990, 335:69-71.
21. Chen S, Kashiwabara H, Kosegawa I, Ishii J, Katayama S: Bradykinin may be not involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor. Clin Exp Hypertens 1996, 18:625-636.
22. Hwang I-S, Ho H, Hoffman BB, Reaven GM: Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987, 10:512-516.
23. Mondon CE, Reaven GM: Evidence of abnormalities of insulin metabolism in rats with spontaneous hypertension. Metabolism 1988, 37:303-305.
24. Lin JL, Asano T, Shibasaki Y, Tsukuda K, Katagiri H, Ishihara H, et al.: Altered expression of glucose transporter isoforms with aging in rats: selective decrease in GLUT4 in the fat tissue and skeletal muscle. Diabetologia 1991, 34:477-482.
25. Kosekawa I, Katayama S, Kikuchi C, Kashiwabawa H, Negishi K, Ishii J, et al.: Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. Hypertens Res 1996, 19:37-41.
26. Laemmli UK: Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature 1970, 270:680-685.
27. Nadler JL, Buchanan T, Natarajan R, Antonipillai I: Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993, 21:1024-1029.
28. Balon TW, Jasman A, Scott S, Meehan WP, Rude RK, Nadler JL: Dietary magnesium prevents fructose-induced insulin insensitivity in rats. Hypertension 1994, 23:1036-1039.
29. Kobayashi M, Iwanishi M, Egawa K: Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 1992, 41: 476-483.
30. Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mosthaf L, et al.: Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 1994, 43:447-453.
31. Hoffman C, Lorentz K, Cola JR: Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazon. Endocrinology 1991, 129:1915-1925.
32. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen JA: Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993, 265:R726-R732.
33. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994, 331:1188-1193.
34. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995, 8:316-320.
35. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD: Effects of Pioglitazone on calcium channels in vascular smooth muscle. Hypertension 1994, 24:170-175.
36. Peuler JD, Johnson BAB, Phare SM, Sowers JR: Sex-specific effects of an insulin secretagogue in stroke-prone hypertensive rats. Hypertension 1993, 22:214-220.
37. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effect of new oral hypoglycemic agent CS-045 in NIDOM subjects. Diabetes Care 1992, 15:193-203.